Spots Global Cancer Trial Database for phase iv
Every month we try and update this database with for phase iv cancer trials from around the world to help patients and their families find trials that might be right for them.
We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
Study title | NCT ID | Conditions | Interventions | Eligibility | Organization | Link |
---|---|---|---|---|---|---|
Observational Study for the Evaluation of Long-term Safety of Radium-223 Used for the Treatment of Metastatic Castration Resistant Prostate Cancer | NCT02141438 | Metastatic Cast... | Radium-223 dich... | 18 Years - | Bayer | |
A Study to Learn More About How Radium-223 Affects the Quality of Life of Colombian Patients With Prostate Cancer That Has Not Responded to Testosterone Lowering Treatment and Has Spread to the Bones, and to Better Understand Its Safety | NCT04681144 | Prostate Cancer | Radium-223-dich... | 18 Years - | Bayer | |
Observational Study for the Evaluation of Long-term Safety of Radium-223 Used for the Treatment of Metastatic Castration Resistant Prostate Cancer | NCT02141438 | Metastatic Cast... | Radium-223 dich... | 18 Years - | Bayer | |
Safety And Efficacy Study Of Sunitinib Malate In Chinese Patients With Imatinib Resistant Or Intolerant Malignant Gastrointestinal Stromal Tumor | NCT00793871 | Gastrointestina... | Sunitinib Malat... | 18 Years - | Pfizer | |
Dose Escalation Of Icotinib In Previously Treated Patients With Routine Dose | NCT01465243 | Non-small Cell ... | Icotinib | 18 Years - 75 Years | Betta Pharmaceuticals Co., Ltd. | |
A Study to Learn More About How Radium-223 Affects the Quality of Life of Colombian Patients With Prostate Cancer That Has Not Responded to Testosterone Lowering Treatment and Has Spread to the Bones, and to Better Understand Its Safety | NCT04681144 | Prostate Cancer | Radium-223-dich... | 18 Years - | Bayer | |
Dose Escalation Of Icotinib In Previously Treated Patients With Routine Dose | NCT01465243 | Non-small Cell ... | Icotinib | 18 Years - 75 Years | Betta Pharmaceuticals Co., Ltd. |